Elevated Lipoprotein(a) Raises Major Cardiovascular Event Risk 30% in 1 in 5 People
Updated
Updated · SciTechDaily · May 12
Elevated Lipoprotein(a) Raises Major Cardiovascular Event Risk 30% in 1 in 5 People
3 articles · Updated · SciTechDaily · May 12
More than 20,000 adults in three NIH trials showed the highest Lp(a) levels were tied to a 30% higher risk of major cardiovascular events over nearly four years.
Those patients were also nearly 50% more likely to die from cardiovascular disease and about 65% more likely to have a stroke, with the excess risk strongest in people already diagnosed with heart disease.
About 7% of participants had a major event, and high Lp(a) was not linked to a greater heart-attack risk, suggesting its strongest signal may be for stroke and cardiovascular death.
One in five people has elevated Lp(a), usually without symptoms and often despite normal standard cholesterol, making a simple blood test a potential tool to identify inherited residual risk.
Researchers presented the findings at SCAI 2026 and said the threshold could help target more aggressive LDL lowering now as Lp(a)-specific treatments move closer.
With a hidden heart risk in 1 of 5 people, why is the crucial blood test almost never ordered by doctors?
New drugs can neutralize a major genetic heart risk. When will these treatments move from trials to the pharmacy?
A genetic risk triples stroke odds but isn't linked to heart attacks. What explains this cardiovascular paradox?
Lp(a) and Cardiovascular Disease: From Universal Testing to Next-Generation Therapies
Overview
The management of elevated lipoprotein(a) [Lp(a)] is rapidly changing, moving from general cholesterol-lowering approaches to new, targeted therapies. Innovative drugs like Pelacarsen and Zerlasiran are in advanced development, aiming to directly reduce Lp(a) levels and potentially transform cardiovascular risk management. At the same time, clinical guidelines now recommend that all adults have their Lp(a) measured at least once, helping to identify more people at risk for heart attacks and strokes. This shift combines better screening, deeper risk assessment, and the promise of new treatments, offering hope for improved prevention of cardiovascular disease.